The pathomechanism and treatment of NMOSD and MOGAD

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune astrocytopathy induced by anti–aquaporin4 (AQP4) antibody and complement. Recently, it is revealed that there is a group of myelin oligodendrocyte glycoprotein (MOG) antibody positive cases in seronegative NMOSD and this MOG antibody associated disease (MOGAD) is now considered as a new disease entity. I would like to focus on the relationship between NMOSD and MOGAD especially on the pathomechanism and future treatment strategy in this symposium.